Aerovate Therapeutics, Inc.

Informe acción NasdaqGM:AVTE

Capitalización de mercado: US$502.7m

Aerovate Therapeutics Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Tim Noyes

Chief Executive Officer (CEO)

US$3.1m

Compensación total

Porcentaje del salario del CEO19.1%
Permanencia del CEO3.1yrs
Participación del CEOn/a
Permanencia media de la dirección2.6yrs
Promedio de permanencia en la Junta Directiva3.2yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

May 24
Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Feb 09
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Oct 17
We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Jul 04
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Feb 28
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Jan 06
A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Oct 14
Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Jan 22
We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Sep 30
Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Tim Noyes en comparación con los beneficios de Aerovate Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

-US$82m

Dec 31 2023US$3mUS$586k

-US$76m

Sep 30 2023n/an/a

-US$70m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$57m

Dec 31 2022US$704kUS$563k

-US$52m

Sep 30 2022n/an/a

-US$45m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$5mUS$437k

-US$23m

Compensación vs. Mercado: La compensación total ($USD3.07M) de Tim está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.42M).

Compensación vs. Ingresos: La compensación de Tim ha aumentado mientras la empresa no es rentable.


CEO

Tim Noyes (62 yo)

3.1yrs

Permanencia

US$3,070,657

Compensación

Mr. Timothy P. Noyes, MBA, also known as Tim, has been the Chief Executive Officer of Aerovate Therapeutics, Inc. since May 2021 and has been its Director since April 2021. Mr. Noyes serves as Venture Part...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Timothy Noyes
CEO & Director3.1yrsUS$3.07msin datos
George Eldridge
CFO & Treasurer3.3yrsUS$2.13m0.0068%
$ 34.2k
Timothy Pigot
Chief Commercial Officer3yrsUS$2.45m0.011%
$ 56.7k
Benjamin Dake
Founder5.9yrsUS$2.88m0.0045%
$ 22.5k
Marinus Verwijs
Chief Technical Officerless than a yearUS$1.32msin datos
Ralph Niven
Chief Scientific Officer1.8yrsUS$433.20k0.0056%
$ 28.1k
Hunter Gillies
Chief Medical Officer4.1yrsUS$1.63m0.019%
$ 97.8k
Donna Dea
Head of Regulatory Affairs3.8yrssin datossin datos
Susan Fischer
Executive Vice President of Development Operations2.2yrssin datossin datos
Stephen Yu
Senior Vice President of Quality1.8yrssin datossin datos
Sanjeev Khindri
Executive Vice President of Clinical Development1.4yrssin datossin datos
Cheryl Lassen
Senior Vice President of Clinical Development1.4yrssin datossin datos

2.6yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AVTE se considera experimentado (2.8 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Timothy Noyes
CEO & Director3.2yrsUS$3.07msin datos
Maha Katabi
Independent Director3.8yrsUS$230.01k0%
$ 0
Christian Schade
Independent Directorless than a yearsin datossin datos
Donald Santel
Independent Director1.4yrsUS$568.54k0%
$ 0
David Grayzel
Independent Director3.8yrsUS$225.99k0%
$ 0
Joshua Resnick
Independent Director3.8yrsUS$174.80k0%
$ 0
Mark Iwicki
Independent Director3.3yrsUS$218.30k0%
$ 0
Allison Dorval
Independent Director2.9yrsUS$185.80k0%
$ 0
Habib Dable
Independent Chairman of the Boardless than a yearUS$363.25k0%
$ 0

3.2yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de AVTE se considera experimentada (3 años de antigüedad promedio).